Moving from opacity to transparency in pharmaceutical policy. - Wikidata - awgldk - TriplyDB

Moving from opacity to transparency in pharmaceutical policy.

Moving from opacity to transparency in pharmaceutical policy.

http://www.wikidata.org/entity/Q36432054

about

The timing of drug funding announcements relative to elections: a case study involving dementia medications Will Open Government make Canada's health agencies more transparent?Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.Regulating prescription drugs for patient safety: does Bill C-17 go far enough?Cost shifting and timeliness of drug formulary decisions in atlantic Canada.Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.The power of "principles" in a national pharmaceuticals strategy Use of product listing agreements by Canadian provincial drug benefit plans.Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.DRUG EVALUATION AND DECISION MAKING IN CATALONIA: DEVELOPMENT AND VALIDATION OF A METHODOLOGICAL FRAMEWORK BASED ON MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR ORPHAN DRUGS.

P2860

Q28486951-65523695-6BD4-4C88-963D-0D70DC0B37C0 Q28741393-D8508C28-C263-439F-ACAA-9AC2D9AD886C Q33395099-A1FE34FB-0D0B-48B0-B76B-DCA4CA6CFDF9 Q33590650-0C4CC368-5990-4420-B6D7-35465C440AD6 Q33701810-6B1404AC-EFE3-441D-B090-D4F88C9A68D3 Q33797377-ACCB6319-9E28-4A56-A28F-22DAD3699D79 Q34086884-0CBBFEB7-AC56-42F4-BF43-DBC38A4367A3 Q35739876-66A559A4-F15F-4CE6-B74B-73DFB1D7AB0B Q35898829-B1D17EB2-2D16-49ED-A83D-86B96E1C3DAB Q37123322-1B28A5EF-2258-413A-B962-39B3F4B45314 Q37723077-D4E9B5F2-D1CE-4EF1-A25D-025382D4959A Q48572824-5A4118A6-C133-4F61-B2B1-96DB9709EE2E Q53836366-0D3843E6-4DD3-408A-8C49-7466B8C4FDB6

P2860

Moving from opacity to transparency in pharmaceutical policy.

http://www.wikidata.org/entity/Q36432054

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Moving from opacity to transparency in pharmaceutical policy.

@ast

Moving from opacity to transparency in pharmaceutical policy.

@en

type

label

Moving from opacity to transparency in pharmaceutical policy.

@ast

Moving from opacity to transparency in pharmaceutical policy.

@en

prefLabel

Moving from opacity to transparency in pharmaceutical policy.

@ast

Moving from opacity to transparency in pharmaceutical policy.

@en

P1433

Q36432054-4B04C1FC-EC31-43C6-BC83-8E3CE0A90D30

P1476

Q36432054-9D4B19C9-712F-4846-92AD-3079FEF6DEF4

P2093

Q36432054-4DCAB77F-42DC-42DA-A509-468880163E78

Q36432054-995785D8-53C4-4043-B0E8-310D68C02C21

P2860

Q36432054-21B4EA75-8A7D-46F3-B4DF-69F3A435F5C9

Q36432054-3114083F-DE48-42F6-9AD7-69472531773B

Q36432054-3452AA44-5478-4DD1-A8C8-BD74BD5E5317

Q36432054-552CC053-F020-48EA-B795-ACCBC756711D

Q36432054-5B55958E-B5FF-45CC-8476-E5ECBD609EFF

Q36432054-5CA92DF4-56D8-4FC0-A448-7836EE914DF9

Q36432054-608CDEE0-F2EB-4D5A-8D9A-FF23E103E09B

Q36432054-6850C227-BFF1-4095-8539-74E3386193D4

Q36432054-A14E9AEA-A72E-4E02-BD51-A88206F8B411

Q36432054-A4A46F3A-5C13-4945-88AB-DA017416835A

P304

Q36432054-7DAC3ABB-EF09-44F0-8DE2-4CA0E8D865F0

P31

Q36432054-04C5F9C0-7021-46EB-A07C-8916155425E5

P356

Q36432054-7BF95BD3-54A2-44FD-B219-FDFB2B3F9F6F

P407

Q36432054-2172C963-F015-435C-9D6B-0A90F5BC3E61

P433

Q36432054-3CE75A0F-18A0-4FE5-8C16-B82D5F5ABE0E

P478

Q36432054-814E1A9F-2B2A-4662-B62F-2C8BE008A246

P577

Q36432054-54ECD705-CDA2-47B2-8A04-95CA23C45E67

P5875

Q36432054-9AD3409F-761D-4EBD-AA70-35A987400F46

P698

Q36432054-100020DE-1641-440B-B10D-E0621A9C0C1D

P932

Q36432054-C964DDD3-C7E6-4F5F-8500-6AA0BA9CA12F

P356

P1433

Canadian Medical Association Journal

P1476

Moving from opacity to transparency in pharmaceutical policy.

@en

P2093

Andreas Laupacis

http://www.w3.org/2001/XMLSchema#string

Irfan Dhalla

http://www.w3.org/2001/XMLSchema#string

P2860

Ghost authorship in industry-initiated randomised trials

Publication bias in clinical research

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

Should commercial-in-confidence data be used by decision makers when making assessments of cost-effectiveness?

Failing the public health--rofecoxib, Merck, and the FDA.

Optimizing the use of prescription drugs in Canada through the Common Drug Review.

Should patient groups accept money from drug companies? No.

Progressive drug licensing: an opportunity to achieve transparency and accountability?

Should patient groups accept money from drug companies? Yes.

Health Canada's Progressive Licensing Framework.

P304

428-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.070799

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5584428

http://www.w3.org/2001/XMLSchema#string

P698

18268270

http://www.w3.org/2001/XMLSchema#string

P932

2228347

http://www.w3.org/2001/XMLSchema#string